Effect of osimertinib in targeted therapy for elderly patients with non-small cell lung cancer and its effect on T lymphocyte levels
Objective To explore the efficacy of ositinib in targeted therapy for elderly non-small cell lung cancer patients and its impact on immune levels.Methods A total of 116 elderly non-small cell lung cancer patients from January 2018 to December 2020 were retrospectively selected as the study subjects.They were divided into two groups based on different treatments,with 58 cases in each group.The control group received conventional radiotherapy and chemotherapy,while the observation group received combined treatment with ositinib and the treatments in the control group.After 3 months of treatment,the patient's condition was evaluated,and the total effective rate,T lymphocyte levels(CD3+,CD4+,CD8+,CD4+/CD8+),tumor marker levels,and incidence of toxic side effects were compared between the two groups.Results The total effective rate of the observation group after 3 months of treatment was 44.8％,which was higher than the control group's 25.9％(P＜0.05);After 3 months of treatment,the levels of CD3+,CD4+,and CD4+/CD8+in both groups were lower than before treatment(P＜0.05).The level of CD8+was higher than that before treatment(P＜0.05);After 6 months of treatment.The levels of CD3+(58.95±4.21)％,CD4+(32.59±3.11)％,and CD4+/CD8+(1.21±0.22)％in the observation group were higher than those in the control group(P＜0.05).The level of CD8+(26.81±3.32)％was lower than the control group(P＜0.05).In the observation group,CA125(91±8)U/ml,CYFRA21-1(1.26±0.24)μg/L,and CEA levels(34±5)μg/L were lower than the control group(P＜0.05).There was no statistically significant difference in the incidence of toxic and side effects between the two groups(P＞0.05).Conclusion Osetinib can achieve good overall effective rate in the targeted treatment of elderly non-small cell lung cancer patients,with lower impact on T lymphocyte levels,reduced tumor marker levels,and no increase in the incidence of toxic side effects.It is worth promoting and applying.
Carcinoma,non-small-cell lungMolecular targeted therapyT-lymphocytesBiomarkers,tumorDrug-related side effects and adverse reactionsOsitinob
NETL
NSTL
万方数据
